AI Summary & Key Takeaways
AI InsightRecurrent DVT or pulmonary embolism was not detected in the patients.Conclusion: According to the current guidelines and literature findings novel oral anticoagulants could be used safely and efficiently as afirst line drug theraphy in DVT patients due to their noninferior effectiveness to warfarin and lower side effect profile.
📌 3 Key Takeaways
Özet
Objectives: This study aims to present the clinical results of patients administered rivaroxaban for the treatment of deep vein thrombosis(DVT) in terms of efficacy and safety.Patients and methods: A total of 78 patients (44 males, 34 females; mean age 60.9±20.6 years; range, 26 to 88 years) diagnosed with DVThad received rivaroxaban treatment at the Gülhane Education and Research Hospital's Cardiovascular Surgery Clinic between August15, 2014 and November 3, 2017 were included in the study. Deep vein thrombosis diagnoses of the patients were confirmed by Dopplerultrasonography. The patients’ epidemiological and biochemical values were evaluated. Major-minor bleeding and recurrence that occurredduring rivaroxaban treatment was investigated.Results: The mean follow-up period was 12.2±9.4 (range, 6-48) months. When anticoagulant treatments of the patients were examined,21 patients (27%) were treated with rivaroxaban as initial treatment and 57 patients (73%) had transitioned from warfarin to rivaroxabantreatment. In patients using rivaroxaban, one patient had hypermenorrhea and two patients had epistaxis. Major bleeding was not detected.While three patients had alanine aminotransferase levels up to two times higher than the normal limit, none of the patients had clinicallysignificant liver or kidney failure. Recurrent DVT or pulmonary embolism was not detected in the patients.Conclusion: According to the current guidelines and literature findings novel oral anticoagulants could be used safely and efficiently as afirst line drug theraphy in DVT patients due to their noninferior effectiveness to warfarin and lower side effect profile.